18. Spinocerebellar degeneration
[
14 clinical trials,
11 drugs（DrugBank:
5 drugs),
20 target genes / 11 target pathways ]
Searched query = "Spinocerebellar degeneration"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04107740 | February 20, 2019 | 14 October 2019 | C-Trelin Orally Disintegrated(OD) Tablet 5mg in Ataxia Due to Spinocerebellar Degeneration | Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IV Clinical Trial to Evaluate and Compare the Safety and Efficacy of C-Trelin OD Tab 5mg(Taltirelin Hydrate) in Patients With Ataxia Induced by Spinocerebellar Degeneration | Spinocerebellar Degeneration | Drug: C-Trelin OD Tab(5mg Taltirelin Hydrate);Drug: Placebo | Chem Tech Research Incorporation | Recruiting | 20 Years | N/A | All | 166 | Phase 4 | Korea, Republic of | |
| 2 | NCT02889302 | November 15, 2016 | 18 December 2018 | An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | An Additional Phase III Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | Spinocerebellar Degeneration | Drug: Placebo;Drug: KPS-0373 | Kissei Pharmaceutical Co., Ltd. | Not recruiting | 20 Years | N/A | All | 203 | Phase 3 | Japan | |
| 3 | JPRN-UMIN000010723 | 2014/01/17 | 21 May 2019 | Therapeutic Effects of Neurofeedback in Neurological Disorders | Therapeutic Effects of Neurofeedback in Neurological Disorders - Therapeutic Effects of Neurofeedback in Neurological Disorders | Parkinsonism Spinocerebellar Degeneration Stroke(with motor deficit[upper limb impairment/ gait and balance disorder]/ with speech dsyfunction) | Subjects are provideed feedback of cortical activity during task, and they are asked to try enhance their cortical activation during task. After baseline clinical assessment, participant were provided Neurofeedback-based training three sessions per week for two weeks. In the Neurofeedback-basesd training, they were asked to imagine gait and balance related motorimagery, and the cortical activation signal were provided as feedback. All participants were provided usual rehabilitative intervention up to 180 min per day for more than 5 times per week, until two weeks passes after neurofeedback intervention were finished. In patients participated study for gait disturbance as primary outcome, daily therapy should include at least 60 minutes of physical therapy. In patients participated study for upper limb paresis as outcome measures, daily therapy should include at least 60 minutes of occupational therapy. In patients participated study for aphasia as primary outcome measures, daily therapy should include at least 60 minutes of speech therapy. Subjects are asked to try enhance their cortical activation during task, but they are provideed cortical activity from other subject. (Control) After baseline clinical assessment, participant were provided Neurofeedback-based training three sessions per week for two weeks. In the Neurofeedback-basesd training, they were asked to imagine gait and balance related motorimagery, and the cortical activation signal were provided as feedback. All participants were provided usual rehabilitative intervention (including at least 60 minutes of physical and/or occupational therapy) up to 180 min per day for more than 5 times per week, until two weeks passes after neurofeedback intervention were finished. In patients participated study for gait disturbance as primary outcome, daily therapy should include at least 60 minutes of physical therapy. In patients participated study for upper limb paresis as outcome measures, daily therapy shoul | Dept. of Neurology, Osaka University Graduate School of Medicine | Morinomiya Hospital Kawasaki Medical School | Not Recruiting | 20years-old | 85years-old | Male and Female | 180 | Phase 2,3 | Japan |
| 4 | NCT01970098 | October 9, 2013 | 18 December 2018 | A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | A Phase III Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | Spinocerebellar Degeneration | Drug: KPS-0373, High dose;Drug: KPS-0373, Low dose;Drug: Placebo | Kissei Pharmaceutical Co., Ltd. | Not recruiting | 20 Years | N/A | All | 374 | Phase 3 | Japan | |
| 5 | NCT01970111 | October 2013 | 25 April 2016 | An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | Spinocerebellar Degeneration | Drug: KPS-0373, High dose;Drug: KPS-0373, Low dose | Kissei Pharmaceutical Co., Ltd. | Not recruiting | 20 Years | N/A | Both | Phase 3 | Japan | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT01970124 | October 2013 | 25 April 2016 | A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | Spinocerebellar Degeneration | Drug: KPS-0373, High dose;Drug: KPS-0373, Low dose | Kissei Pharmaceutical Co., Ltd. | Not recruiting | 20 Years | N/A | Both | Phase 3 | Japan | |||
| 7 | NCT01970137 | October 2013 | 25 April 2016 | A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | Spinocerebellar Degeneration | Drug: KPS-0373, High dose;Drug: KPS-0373, Low dose | Kissei Pharmaceutical Co., Ltd. | Not recruiting | 20 Years | N/A | Both | Phase 3 | Japan | |||
| 8 | JPRN-UMIN000011560 | 2013/08/30 | 2 April 2019 | Trial of varenicline (Champix) for the treatment of spinocerebellar degeneration | spinocerebellar degeneration (SCD) | [High-dose Group] Oral administration of varenicline 1-7 days 0.5 mg/day 8-14 days 1.0mg/day 15-21 days 1.5mg/day 22-56 days 2.0 mg/day 57-63 days 1.0 mg/day 64-70 days 0.5 mg/day 71-84 days Wash-out period 85-154 days 0.5 mg/day [Low-dose Group] Oral administration of varenicline 1-70 days 0.5 mg/day 71-84 days Wash-out period 85-91 days 0.5 mg/day 92-98 days 1.0mg/day 99-105 days 1.5mg/day 106-140 days 2.0 mg/day 141-147 days 1.0 mg/day 148-154 days 0.5 mg/day | Niigata University | Recruiting | 20years-old | Not applicable | Male and Female | 40 | Phase 1,2 | Japan | ||
| 9 | JPRN-UMIN000011111 | 2013/07/16 | 2 April 2019 | Spinal blood flow and metabolism in neurological diseases | motor neuron disease including ALS, multiple sclerosis, stroke, Parkinson disease, spinocerebellar degeneration, multiple system atrophy | PET scan study with 11C-flumazenil PET scan study with 18F- FDG PET scan study with 15O-H2O | Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences | Recruiting | 20years-old | Not applicable | Male and Female | 70 | Not applicable | Japan | ||
| 10 | NCT01384435 | June 2011 | 19 February 2015 | A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | A Randomized, Double Blind, Placebo-controlled Phase II Study of KPS-0373 in Patients With SCD | SCD | Drug: KPS-0373;Drug: Placebo | Kissei Pharmaceutical Co., Ltd. | Not recruiting | 20 Years | N/A | Both | 200 | Phase 2 | Japan | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT01004016 | October 2009 | 19 February 2015 | A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | A Double-blind, Placebo-controlled, Crossover Study, Followed by Open-label Study of KPS-0373 in Patients With SCD | Spinocerebellar Degeneration | Drug: KPS-0373;Drug: Placebo | Kissei Pharmaceutical Co., Ltd. | Not recruiting | 20 Years | N/A | Both | 20 | Phase 2 | Japan | |
| 12 | NCT00863538 | November 2004 | 19 February 2015 | Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | An Open-label, Phase II Study of KPS-0373 in Patients With SCD | Spinocerebellar Degeneration | Drug: KPS-0373 | Kissei Pharmaceutical Co., Ltd. | Not recruiting | 20 Years | N/A | Both | 40 | Phase 2 | Japan | |
| 13 | NCT00034242 | April 2002 | 19 February 2015 | High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration | The Efficacy of High-Dose Intravenous Immunoglobulin Therapy In Patients With Cerebellar Degeneration: A Double Blind, Placebo Controlled Trial | Spinocerebellar Degenerations | Drug: high-dose intravenous immunoglobulin (IVIG) | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | N/A | N/A | Both | 20 | Phase 2 | United States | |
| 14 | JPRN-JapicCTI-050031 | 23 April 2019 | Intrathecal Baclofen therapy with the implanted pump system for Spastic Palsy (Post-marketing clinical trial extended phase 3 after NDA approval) | Intrathecal Baclofen therapy with the implanted pump system for Spastic Palsy (Post-marketing clinical trial extended phase 3 after NDA approval) | [Spinal cord Origin] Spinal cord Injury, Multiple sclerosis, Spinocerebellar degeneration, Circulatory disorder of the spinal, Ossification of the posterior longitudinal ligament [Cerebral Origin] Cerebral palsy, Traumatic head injury | Intervention name : Baclofen Dosage And administration of the intervention : Intertheacal injection | DAIICHI SANKYO COMPANY, LIMITED | BOTH | Phase 4 |